Immunoreactivity of Pluripotent Markers SSEA-5 and L1CAM in Human Tumors, Teratomas, and Induced Pluripotent Stem Cells.

Journal of biomarkers Pub Date : 2013-01-01 Epub Date: 2013-05-27 DOI:10.1155/2013/960862
Linda Cassidy, Meerim Choi, Jason Meyer, Rui Chang, Gail M Seigel
{"title":"Immunoreactivity of Pluripotent Markers SSEA-5 and L1CAM in Human Tumors, Teratomas, and Induced Pluripotent Stem Cells.","authors":"Linda Cassidy,&nbsp;Meerim Choi,&nbsp;Jason Meyer,&nbsp;Rui Chang,&nbsp;Gail M Seigel","doi":"10.1155/2013/960862","DOIUrl":null,"url":null,"abstract":"<p><p>Pluripotent stem cell markers can be useful for diagnostic evaluation of human tumors. The novel pluripotent marker stage-specific embryonic antigen-5 (SSEA-5) is expressed in undifferentiated human induced pluripotent cells (iPSCs), but little is known about SSEA-5 expression in other primitive tissues (e.g., human tumors). We evaluated SSEA-5 immunoreactivity patterns in human tumors, cell lines, teratomas, and iPS cells together with another pluripotent cell surface marker L1 cell adhesion molecule (L1CAM). We tested two hypotheses: (1) SSEA-5 and L1CAM would be immunoreactive and colocalized in human tumors; (2) SSEA-5 and L1CAM immunoreactivity would persist in iPSCs following retinal differentiating treatment. SSEA-5 immunofluorescence was most pronounced in primitive tumors, such as embryonal carcinoma. In tumor cell lines, SSEA-5 was highly immunoreactive in Capan-1 cells, while L1CAM was highly immunoreactive in U87MG cells. SSEA-5 and L1CAM showed colocalization in undifferentiated iPSCs, with immunopositive iPSCs remaining after 20 days of retinal differentiating treatment. This is the first demonstration of SSEA-5 immunoreactivity in human tumors and the first indication of SSEA-5 and L1CAM colocalization. SSEA-5 and L1CAM warrant further investigation as potentially useful tumor markers for histological evaluation or as markers to monitor the presence of undifferentiated cells in iPSC populations prior to therapeutic use. </p>","PeriodicalId":91105,"journal":{"name":"Journal of biomarkers","volume":"2013 ","pages":"960862"},"PeriodicalIF":0.0000,"publicationDate":"2013-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1155/2013/960862","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of biomarkers","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2013/960862","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2013/5/27 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 2

Abstract

Pluripotent stem cell markers can be useful for diagnostic evaluation of human tumors. The novel pluripotent marker stage-specific embryonic antigen-5 (SSEA-5) is expressed in undifferentiated human induced pluripotent cells (iPSCs), but little is known about SSEA-5 expression in other primitive tissues (e.g., human tumors). We evaluated SSEA-5 immunoreactivity patterns in human tumors, cell lines, teratomas, and iPS cells together with another pluripotent cell surface marker L1 cell adhesion molecule (L1CAM). We tested two hypotheses: (1) SSEA-5 and L1CAM would be immunoreactive and colocalized in human tumors; (2) SSEA-5 and L1CAM immunoreactivity would persist in iPSCs following retinal differentiating treatment. SSEA-5 immunofluorescence was most pronounced in primitive tumors, such as embryonal carcinoma. In tumor cell lines, SSEA-5 was highly immunoreactive in Capan-1 cells, while L1CAM was highly immunoreactive in U87MG cells. SSEA-5 and L1CAM showed colocalization in undifferentiated iPSCs, with immunopositive iPSCs remaining after 20 days of retinal differentiating treatment. This is the first demonstration of SSEA-5 immunoreactivity in human tumors and the first indication of SSEA-5 and L1CAM colocalization. SSEA-5 and L1CAM warrant further investigation as potentially useful tumor markers for histological evaluation or as markers to monitor the presence of undifferentiated cells in iPSC populations prior to therapeutic use.

Abstract Image

Abstract Image

Abstract Image

多能标记物SSEA-5和L1CAM在人肿瘤、畸胎瘤和诱导多能干细胞中的免疫反应性
多能干细胞标记物可用于人类肿瘤的诊断评价。这种新的多能性标志物阶段特异性胚胎抗原-5 (SSEA-5)在未分化的人诱导多能细胞(iPSCs)中表达,但对SSEA-5在其他原始组织(如人类肿瘤)中的表达知之甚少。我们评估了SSEA-5在人类肿瘤、细胞系、畸胎瘤和iPS细胞中的免疫反应模式,以及另一种多能细胞表面标记物L1细胞粘附分子(L1CAM)。我们检验了两个假设:(1)SSEA-5和L1CAM在人类肿瘤中具有免疫反应性和共定位;(2) SSEA-5和L1CAM免疫反应性在视网膜分化处理后的iPSCs中持续存在。SSEA-5免疫荧光在原始肿瘤(如胚胎癌)中最为明显。在肿瘤细胞系中,SSEA-5在Capan-1细胞中具有高度免疫反应,而L1CAM在U87MG细胞中具有高度免疫反应。SSEA-5和L1CAM在未分化的iPSCs中显示共定位,在视网膜分化治疗20天后仍有免疫阳性的iPSCs存在。这是SSEA-5在人类肿瘤中的首次免疫反应性证明,也是SSEA-5与L1CAM共定位的第一个适应症。SSEA-5和L1CAM作为潜在有用的肿瘤标志物,值得进一步研究,用于组织学评估或作为标志物,监测治疗前iPSC群体中未分化细胞的存在。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信